Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DNA Vaccine
Linkage of antigen to filamentous bacteriophage coat protein enhances DNA vaccine potency
May 10th, 2006
Linkage of antigen to filamentous bacteriophage coat protein III domain I enhanced DNA vaccine potency. "Although DNA-based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumor antigens are weak and fail to generate a vigorous immune response in tumor-bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune-activating genes to the tumor antigen sequence," noted scientists in Spain and Denmark. "In this work, we converted a model non-immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage...
Source: Vaccine Weekly (2006-05-10)
|
